Cresco Spine earned FDA 510(k) clearance for its spring distraction system, the company said in a Jan. 19 LinkedIn post.
The SDS implant is designed for addressing early onset scoliosis, and it previously earned the FDA’s Breakthrough Device Designation.
Cresco Spine plans a controlled release of SDS in the U.S. and Canada.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
